SUMO2P21: A Potential Drug Target and Biomarker (G728825)

Target Name: SUMO2P21

NCBI ID: G728825

SUMO2P21

Other Name(s): SUMO2 pseudogene 21 | LOC728825 | Small ubiquitin-like modifier 2

SUMO2P21: A Potential Drug Target and Biomarker

SUMO2P21, also known as SUMO2 pseudogene 21, is a gene that has been identified in the human body as a potential drug target and biomarker. The SUMO2P21 gene is located on chromosome 16 and encodes a protein known as SUMO2, which is a key regulator of microtubules in cells. Microtubules are dynamic structures that play a critical role in the movement of cells, and alterations in microtubule dynamics have been implicated in a wide range of diseases, including cancer, neurodegenerative diseases, and developmental disorders.

SUMO2 has been shown to play a key role in the regulation of cell division, and is often missregulated in cancer cells. It has also been implicated in the development and progression of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. SUMO2 has also been shown to be involved in the regulation of stem cell proliferation and the maintenance of stem cell self-renewal.

SUMO2P21 has also been identified as a potential biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and cardiovascular disease. It has been shown to be expressed in a variety of tissues and cells, including cancer cells, neurons, and immune cells. SUMO2P21 has also been shown to be involved in the regulation of cellular processes that are important for disease progression, such as the angiogenesis (the formation of new blood vessels) and the maintenance of stem cell stemness.

In addition to its potential as a drug target and biomarker, SUMO2P21 is also of interest as a potential therapeutic target for a variety of diseases. For example, SUMO2 has been shown to play a role in the regulation of mitochondrial function, and alterations in mitochondrial function have been implicated in a wide range of diseases, including cancer, neurodegenerative diseases, and cardiovascular disease. Therefore, inhibiting SUMO2P21 activity may be a potential therapeutic approach for treating these diseases.

SUMO2P21 has also been shown to be involved in the regulation of cellular signaling pathways that are important for disease progression. For example, SUMO2 has been shown to play a role in the regulation of the TGF-β pathway, a signaling pathway that is involved in the regulation of cell growth, angiogenesis, and the maintenance of stem cell stemness. Therefore, inhibiting SUMO2P21 activity may be a potential therapeutic approach for treating diseases that are characterized by the over-expression of TGF-β signaling pathway.

In conclusion, SUMO2P21 is a gene that has the potential to be a drug target and biomarker for a variety of diseases. Its involvement in the regulation of microtubule dynamics and cellular signaling pathways suggests that it may be a useful target for the development of new therapeutic approaches for a wide range of diseases. Further research is needed to fully understand the role of SUMO2P21 in disease progression and the development of new therapeutic approaches.

Protein Name: SUMO2 Pseudogene 21

The "SUMO2P21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SUMO2P21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets